Using Failure Mode, Effect and Criticality Analysis to improve safety in the cancer treatment prescription and administration process

• Published in: Journal of pharmaceutical policy and practice 2023-01, Vol.16 (1), p.9-9
• Main Authors: Buja, Alessandra, De Luca, Giuseppe, Ottolitri, Ketti, Marchi, Elena, De Siena, Francesco Paolo, Leone, Giovanni, Maculan, Pietro, Bolzonella, Umberto, Caberlotto, Riccardo, Cappella, Giovanni, Grotto, Giulia, Lattavo, Gaia, Sforzi, Benedetta, Venturato, Giovanni, Saieva, Anna Maria, Baldo, Vincenzo
• Format: Article
• Language: English
• Subjects: Analysis; Cancer; Cancer therapies; Cancer treatment; Chemotherapy; Chemotherapy administration; Drug approval; Drug dosages; Failure; Hospitals; Medical errors; Oncology; Outpatient care facilities; Patient safety; Proactive management; Public health; Risk assessment; Safety and security measures
• ISSN: 2052-3211; 2052-3211
• DOI: 10.1186/s40545-023-00512-9

Administering cancer drugs is a high-risk process, and mistakes can have fatal consequences. Failure Mode, Effect and Criticality Analysis (FMECA) is a widely recognized method for identifying and preventing potential risks, applied in various settings, including healthcare. The aim of this study was to recognize potential failures in cancer treatment prescription and administration, with a view to enabling the adoption of measures to prevent them. This study consists of a FMECA. A team of resident doctors in public health at the University of Padua examined the cancer chemotherapy process with the support of a multidisciplinary team from the Veneto Institute of Oncology (an acknowledged comprehensive cancer center), and two other provincial hospitals. A diagram was drafted to illustrate 9 different phases of chemotherapy, from the adoption of a treatment plan to its administration, and to identify all possible failure modes. Criticality was ascertained by rating severity, frequency and likelihood of a failure being detected, using adapted versions of already published scales. Safety strategies were identified and summarized. Twenty-two failure modes came to light, distributed over the various phases of the cancer treatment process, and seven of them were classified as high risk. All phases of the cancer chemotherapy process were defined as potentially critical and at least one action was identified for a single high-risk failure mode. To reduce the likelihood of the cause, or to improve the chances of a failure mode being detected, a total of 10 recommendations have been identified. FMECA can be useful for identifying potential failures in a process considered to be at high risk. Safety strategies were devised for each high-risk failure mode identified.